GTC Berlin: NVIDIA Expands AI Partnerships Across Healthcare

GTC Berlin, NVIDIA’s flagship European conference, brings together technology leaders, researchers and industry executives to explore the latest advances in AI, robotics and accelerated computing.

This year, healthcare and life sciences are among the sectors in focus, with NVIDIA announcing a series of collaborations spanning precision cancer care, protein design and AI-powered drug discovery.

The announcements reflect the growing role of agentic AI in scientific research and clinical workflows, alongside physical AI that connects intelligent software with real-world systems.

“Agentic and physical AI are opening new possibilities across medicine, from designing proteins and powering autonomous laboratories to improving personalised cancer care,” says Kimberly Powell, Vice President of Healthcare at NVIDIA.

“Together with healthcare and life science leaders, we’re accelerating scientific discovery and advancing more precise, accessible care around the world.”

Among the announcements is a collaboration with Siemens Healthineers to develop the next generation of adaptive radiotherapy, bringing together agentic AI, patient-specific simulation and robotic intelligence to support more personalised cancer treatment.

Advancing personalised cancer care

By 2050, approximately 35 million people worldwide are projected to be diagnosed with cancer each year, placing further pressure on healthcare systems to deliver effective, precise treatment at scale.

Against this backdrop, NVIDIA and Siemens Healthineers are combining their respective expertise in accelerated computing, imaging and oncology to simplify radiotherapy workflows and help expand access to cancer care.

The collaboration will explore how AI can support adaptive radiotherapy, which enables treatment to be tailored to an individual patient rather than relying solely on a fixed plan. This approach aims to help clinicians deliver prescribed radiation doses to tumours while protecting surrounding healthy tissue.

At the heart of the initiative is the use of NVIDIA Nemotron open foundation models to support agentic co-planning, helping oncologists evaluate and refine personalised treatment strategies. These models could be combined with NVIDIA CUDA-accelerated dose calculations to enable rapid, patient-specific simulations.

Meanwhile, the NVIDIA Holoscan platform could connect live sensor data with AI and simulation, supporting treatment adjustments in real time.

David Niewolny, Global Head of Healthcare and Medical Business Development at NVIDIA, believes the collaboration demonstrates how technology partnerships could reshape cancer treatment.

“The future of cancer treatment will be personalised, adaptive and AI-powered,” he writes on LinkedIn.

Niewolny highlights the involvement of Siemens Healthineers’ cancer care business, Varian, in bringing together agentic AI, physical AI and accelerated computing to advance radiotherapy.

“This is a wonderful example of how ecosystem collaboration can redefine cancer care and expand access to care globally,” he says.

Personalisation is central to the initiative, according to Arthur Kaindl, Head of Varian, who believes treatment should be adapted to individual patients rather than expecting patients to fit a standardised approach.

“Adaptive radiotherapy is built on a single principle: treatment should adapt to the patient, not the other way around,” says Kaindl.

He adds that the collaboration with NVIDIA will explore “how AI and real-time computing could give clinicians greater speed and insight to make informed decisions, adapt treatment with greater confidence and deliver personalised care to more patients”.

Expanding the possibilities of protein design

Beyond cancer care, NVIDIA is working with research organisations to apply AI to one of the fundamental challenges in biology: designing proteins with specific, useful functions.

In collaboration with the UW Medicine Institute for Protein Design, NVIDIA has introduced RFD4-Proteina, an open model within its BioNeMo platform that combines programmable protein design with search capabilities.

Proteins perform a wide range of biological functions, making the ability to design new ones a potentially valuable tool for drug discovery and diagnostics. However, identifying a protein capable of performing a particular task requires researchers to navigate an immense range of possible designs.

RFD4-Proteina aims to streamline this process by enabling scientists and AI agents to generate, search and refine targeted protein designs using molecular inputs, constraints and scoring objectives. Potential applications include designing proteins that interrupt disease processes or detect signs of disease in diagnostic tests.

The model is intended to help researchers explore and prioritise promising candidates for laboratory testing, where experiments can establish whether a design performs as intended.

David Baker, Director of the Institute for Protein Design at the University of Washington, sees the model as an opportunity to broaden the scope of what scientists can achieve.

“RFD4-Proteina expands what scientists can create, from proteins that could advance drug discovery to enzymes that break down pesticides,” says Baker.

“Making the model open will allow researchers around the world to build on these capabilities and pursue solutions once beyond the reach.”

RFD4-Proteina is available through a range of partners, including Amazon Bio Discovery, Anthropic’s Claude Science, Google Cloud and Hugging Face. The integrations are intended to help researchers incorporate protein design into AI agent, cloud computing and scientific research workflows.

NVIDIA - key partners

Siemens Healthineers

CEO: Dr Bernd Montag | HQ: Munich, Germany

Siemens Healthineers develops medical imaging, diagnostics and cancer treatment technologies. Its collaboration with NVIDIA focuses on advancing adaptive radiotherapy through agentic AI, patient-specific simulations and real-time computing. Working with its Varian cancer care business, the company aims to help clinicians personalise treatment plans, improve decision-making and extend access to precision cancer care.

Danaher

CEO: Julie Sawyer Montgomery | HQ: Washington, DC

Danaher is a global science and technology group operating across life sciences, diagnostics and biotechnology. Through its Genedata business, it is working with NVIDIA to develop an AI co-scientist that coordinates protein design and testing within an autonomous laboratory. The workflow incorporates RFD4-Proteina, using experimental results to inform successive rounds of protein design and accelerate research.